An HTLV-1-Infected Humanized Mouse Model Expressing HLA-A*02:01 Demonstrates Effective CTL-Mediated Suppression of HTLV-1
Viruses · 2025
DOI: 10.3390/v17091249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Shinsuke Nakajima und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Medicine, Kansai Medical University, Hirakata 573-1010, Japan. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, T-Lymphocytes, Cytotoxic, HLA-A2 Antigen, HTLV-I Infections. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human T-cell leukemia virus type 1 (HTLV-1) establishes lifelong infection and is associated with severe diseases such as adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Cytotoxic T lymphocytes (CTLs), especially those specific for the viral protein Tax, play a pivotal role in controlling HTLV-1 infection. However, conventional humanized mouse models fail to fully reconstitute human immune responses, limiting their utility for evaluating CTL-mediated immunity. This study aimed to establish a physiologically relevant in vivo model to investigate human CTL responses against HTLV-1. To achieve this, we utilized NOG-HLA-A02 transgenic (Tg) mice expressing human HLA-A02:01 on thymic epithelial cells, enabling proper development of HLA-restricted human T cells. Compared to conventional humanized NOG mice, HTLV-1-infected humanized NOG-HLA-A02 Tg mice exhibited significantly reduced HTLV-1 proviral load (PVL), decreased expansion of infected CD4+ T cells, a trend toward increased frequencies of Tax-specific CD8+ T cells, and prolonged survival. These results demonstrate that the expression of HLA-A02:01 facilitates robust CTL-mediated immune control of HTLV-1. This model provides a powerful platform for dissecting HTLV-1 immunopathogenesis and evaluating CTL-targeted therapeutic strategies, including vaccines and immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Medicine, Kansai Medical University, Hirakata 573-1010, Japan.
- Central Institute for Experimental Medicine and Life Science (CIEM), Kawasaki 210-0821, Japan.
- Department of Model Animal, Institute of Biomedical Science, Kansai Medical University, Hirakata 573-1010, Japan.
- Center for Next Generation Biologics Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 208-0011, Japan.
- Department of Clinical Laboratory, Subaru Health Insurance Society Ota Memorial Hospital, Gunma 373-8585, Japan.
ORCID-Profile: Motohito Goto, Sung-Il Lee, Takaharu Ueno, Riichi Takahashi, Mamoru Ito, Kazu Okuma
Zitieren
APA
Nakajima, S., Goto, M., Lee, S. I., Odaka, T., Hino, M., Tezuka, K., Takenouchi, N., Ueno, T., Admadiani, F. R., Takahashi, R., Hamaguchi, I., Takahashi, T., Ito, M., & Okuma, K. (2025). An HTLV-1-Infected Humanized Mouse Model Expressing HLA-A*02:01 Demonstrates Effective CTL-Mediated Suppression of HTLV-1. Viruses. https://doi.org/10.3390/v17091249
Vancouver
Nakajima S, Goto M, Lee SI, Odaka T, Hino M, Tezuka K, et al. An HTLV-1-Infected Humanized Mouse Model Expressing HLA-A*02:01 Demonstrates Effective CTL-Mediated Suppression of HTLV-1. Viruses. 2025. doi:10.3390/v17091249
BibTeX
@article{Nakajima2025,
author = {Nakajima, Shinsuke and Goto, Motohito and Lee, Sung-Il and Odaka, Tokifumi and Hino, Masaki and Tezuka, Kenta and Takenouchi, Norihiro and Ueno, Takaharu and Admadiani, Fhahira Rizkhika and Takahashi, Riichi and Hamaguchi, Isao and Takahashi, Takeshi and Ito, Mamoru and Okuma, Kazu},
title = {An HTLV-1-Infected Humanized Mouse Model Expressing HLA-A*02:01 Demonstrates Effective CTL-Mediated Suppression of HTLV-1},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17091249}
}
EUVIMED